Improvement effect and safety of overactive bladder symptoms
- Conditions
- OABD053201Overactive bladder
- Registration Number
- JPRN-jRCTs061220050
- Lead Sponsor
- Fukata Satoshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
All of the following criteria must be met in order to
participate in this trial.
1.Patients with overactive bladder over 30 years
old
2.Patients with overactive bladder who consented
to participate in the study in writing
If any of the following criteria are met, the patient
will not be allowed to participate in this trial.
1.Patients with organic disease of the urinary tract
2.Patients with neurogenic overactive bladder
3.Patients with malignant tumors of the urinary sys
tem
4.Patients with cognitive dysfunction or psychiatri
c disorders that are difficult to conduct research
5.Patients who are allergic to 5-ALA
6.Patients with porphyria
7.Patients with drug hypersensitivity such as iron a
llergy
8.Pregnant women or patients who may become p
regnant
9.Patients who did not consent to participate in th
e study in writing
10.Patients disqualified by a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OABSS (Amount of change from baseline in OABSS<br>after 12 weeks)
- Secondary Outcome Measures
Name Time Method (1) OABSS (Amount of change from baseline in OA<br>BSS after 4 weeks)<br>(2) Change in residual urine volume from baseline<br>(3) Amount of change from baseline in OABq-SF